Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Nordic Nanovector ASA ( (DE:8NN) ) just unveiled an update.
Thor Medical ASA has successfully completed a private placement, resulting in a share capital increase by registering 23,396,380 new shares from the second tranche of the placement. This initiative raised NOK 157.5 million, increasing the total share capital to NOK 60,777,755, divided into 303,888,775 shares. Each share carries a nominal value of NOK 0.20 and a voting right in the company’s general meeting. This move strengthens the company’s financial position, potentially enhancing its market presence and operational capacity within the radiopharmaceutical industry.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier of radionuclides, primarily focusing on alpha particle emitters derived from naturally occurring thorium. The company employs a proprietary process that does not require irradiation or nuclear reactors, ensuring a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
YTD Price Performance: -10.0%
Average Trading Volume: 5,744
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €59.78M
See more data about 8NN stock on TipRanks’ Stock Analysis page.
